英国 2022/23 季度末初级保健中流感疫苗的有效性。

IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES
Heather J. Whitaker, Naoma Willam, Simon Cottrell, Rosalind Goudie, Nick Andrews, Josie Evans, Catherine Moore, Utkarsh Agrawal, Katie Hassell, Rory Gunson, Jana Zitha, Sneha Anand, Praveen Sebastian-Pillai, Panoraia Kalapotharakou, Cecilia Okusi, Katja Hoschler, Gavin Jamie, Beatrix Kele, Mark Hamilton, Anastasia Couzens, Catherine Quinot, Kathleen Pheasant, Rachel Byford, Kimberly Marsh, Chris Robertson, Simon de Lusignan, Christopher Williams, Maria Zambon, Jim McMenamin, Conall H. Watson
{"title":"英国 2022/23 季度末初级保健中流感疫苗的有效性。","authors":"Heather J. Whitaker,&nbsp;Naoma Willam,&nbsp;Simon Cottrell,&nbsp;Rosalind Goudie,&nbsp;Nick Andrews,&nbsp;Josie Evans,&nbsp;Catherine Moore,&nbsp;Utkarsh Agrawal,&nbsp;Katie Hassell,&nbsp;Rory Gunson,&nbsp;Jana Zitha,&nbsp;Sneha Anand,&nbsp;Praveen Sebastian-Pillai,&nbsp;Panoraia Kalapotharakou,&nbsp;Cecilia Okusi,&nbsp;Katja Hoschler,&nbsp;Gavin Jamie,&nbsp;Beatrix Kele,&nbsp;Mark Hamilton,&nbsp;Anastasia Couzens,&nbsp;Catherine Quinot,&nbsp;Kathleen Pheasant,&nbsp;Rachel Byford,&nbsp;Kimberly Marsh,&nbsp;Chris Robertson,&nbsp;Simon de Lusignan,&nbsp;Christopher Williams,&nbsp;Maria Zambon,&nbsp;Jim McMenamin,&nbsp;Conall H. Watson","doi":"10.1111/irv.13295","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those &gt; 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell-based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The paper provides evidence of moderate influenza VE in 2022/23.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13295","citationCount":"0","resultStr":"{\"title\":\"End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain\",\"authors\":\"Heather J. Whitaker,&nbsp;Naoma Willam,&nbsp;Simon Cottrell,&nbsp;Rosalind Goudie,&nbsp;Nick Andrews,&nbsp;Josie Evans,&nbsp;Catherine Moore,&nbsp;Utkarsh Agrawal,&nbsp;Katie Hassell,&nbsp;Rory Gunson,&nbsp;Jana Zitha,&nbsp;Sneha Anand,&nbsp;Praveen Sebastian-Pillai,&nbsp;Panoraia Kalapotharakou,&nbsp;Cecilia Okusi,&nbsp;Katja Hoschler,&nbsp;Gavin Jamie,&nbsp;Beatrix Kele,&nbsp;Mark Hamilton,&nbsp;Anastasia Couzens,&nbsp;Catherine Quinot,&nbsp;Kathleen Pheasant,&nbsp;Rachel Byford,&nbsp;Kimberly Marsh,&nbsp;Chris Robertson,&nbsp;Simon de Lusignan,&nbsp;Christopher Williams,&nbsp;Maria Zambon,&nbsp;Jim McMenamin,&nbsp;Conall H. Watson\",\"doi\":\"10.1111/irv.13295\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those &gt; 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell-based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The paper provides evidence of moderate influenza VE in 2022/23.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13295\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.13295\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13295","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:在英国的2022/23流感季节,流感活动在经历了两个低流感活动季节后恢复到流行前水平。流感季节初期以甲型(H3N2)流感为主,并伴有甲型(H1N1)流感,在2022年12月底达到高峰,而在流感季节后期,乙型流感的流行水平较低。从 2022 年 9 月到 2023 年 3 月,流感疫苗免费提供给英国本土所有 2-13 岁(苏格兰和威尔士为 14-15 岁)、49 岁以下有临床风险的成年人以及 50 岁及以上的成年人:方法:采用阴性试验设计,计算季节末调整后的疫苗有效性(VE)估计值,并对潜在的混杂因素进行调整:结果:在英国本土,所有年龄大于 65 岁的人群(其中大多数人接种了佐剂四价疫苗)在季节末接种经实验室确诊的流感疫苗的有效率为 30%(95% CI:-6% 至 54%)。18-64 岁人群的 VE 为 47%(95% CI:37%-56%),他们大多接种细胞型疫苗。主要接种减毒活疫苗的 2-17 岁儿童的总体可接种率为 66%(95% CI:53%-76%):本文提供了 2022/23 年流感病毒流行率适中的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain

End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain

Background

The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.

Methods

End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.

Methods

Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell-based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).

Conclusion

The paper provides evidence of moderate influenza VE in 2022/23.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
4.50%
发文量
120
审稿时长
6-12 weeks
期刊介绍: Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信